Cellectis went public in the USA with a stock price increase of 3.5% to $2.66. Prior to this, Bell received the orphan drug designation for allogeneic Car T product for acute lymphoblastic leukemia patients.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.